Viking Therapeutics to participate in Raymond James Biotech/BioPharma Conference 2026 and Piper Sandler Spring Biopharma Symposium 2026

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX) announced that it will attend multiple upcoming investor conferences, with management participating in 1-on-1 meetings.

Investor conference schedule

• Raymond James Biotech/BioPharma Conference 2026

  Management will participate in 1-on-1 meetings.

  Date: April 14, 2026
  Location: New York, NY

• Piper Sandler Spring Biopharma Symposium 2026

  Management will participate in 1-on-1 meetings.

  Date: April 16, 2026
  Location: Boston, MA

Company overview

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company’s research and development leverages its expertise in metabolism to develop therapeutics intended to improve patients’ lives.

Key clinical programs

VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Viking is evaluating a subcutaneous formulation of VK2735 in a Phase 3 obesity program that includes two Phase 3 clinical trials, VANQUISH-1 and VANQUISH-2. The company also is evaluating an oral formulation of VK2735 in obesity. Viking reported that data from a Phase 1 and Phase 2 trial of subcutaneous VK2735 showed an encouraging safety and tolerability profile and positive signs of clinical benefit.

VK2809 is an orally available, small molecule selective thyroid hormone receptor beta agonist being developed for lipid and metabolic disorders. Viking reported that VK2809 achieved both the primary and secondary endpoints in a Phase 2b study for biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients treated with VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with placebo.

Viking’s newest program is evaluating internally developed dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic disorders.

VK0214 is an orally available, small molecule selective thyroid hormone receptor beta agonist being developed in the rare disease space for X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, Viking reported that VK0214 was safe and well-tolerated and drove significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids compared with placebo.

For more information about Viking Therapeutics, visit www.vikingtherapeutics.com.